CAMRELIZUMAB for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 9 adverse event reports in the FDA FAERS database where CAMRELIZUMAB was used for Neoplasm malignant.
Most Reported Side Effects for CAMRELIZUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Myelosuppression | 70 | 16.3% | 4 | 29 |
| Fatigue | 60 | 14.0% | 13 | 3 |
| Nausea | 60 | 14.0% | 11 | 2 |
| Vomiting | 59 | 13.8% | 11 | 3 |
| Diarrhoea | 54 | 12.6% | 5 | 6 |
| Anaemia | 53 | 12.4% | 11 | 4 |
| Hypothyroidism | 53 | 12.4% | 7 | 2 |
| Off label use | 52 | 12.1% | 15 | 9 |
| Rash | 50 | 11.7% | 6 | 1 |
| Thrombocytopenia | 46 | 10.7% | 6 | 5 |
| Reactive capillary endothelial proliferation | 41 | 9.6% | 12 | 5 |
| Therapy partial responder | 38 | 8.9% | 0 | 4 |
| Leukopenia | 37 | 8.6% | 9 | 3 |
| Pyrexia | 37 | 8.6% | 5 | 5 |
| Alanine aminotransferase increased | 33 | 7.7% | 4 | 1 |
Other Indications for CAMRELIZUMAB
Hepatocellular carcinoma (62)
Hepatic cancer (36)
Non-small cell lung cancer (25)
Tumour thrombosis (17)
Squamous cell carcinoma of the hypopharynx (16)
Oesophageal squamous cell carcinoma (15)
Lung neoplasm malignant (14)
Lung adenocarcinoma (13)
Gastric cancer (12)
Colorectal cancer metastatic (8)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)